오늘의 자폐 스펙트럼 장애(ASD) 연구 TOP — 2026-07-13

오늘의 핵심 연구

1. Landmark Autism Research Finds Phelan-McDermid Syndrome May Affect 1 in 7,300 People

• Author/Affiliation: Seaver Autism Center for Research and Treatment, Mount Sinai
• Journal/Source: Autism Research, published June 28, 2026
• Study Design: Prevalence re-estimation via systematic review and meta-analysis
• Sample: Integrated epidemiological data from multiple countries
• Key Findings: The prevalence of Phelan-McDermid syndrome (PMS) has been re-evaluated to 1/7,300, which is approximately 10 times higher than previous estimates. This highlights PMS as a significantly high-frequency single genetic cause of ASD.
• Clinical/Research Implications: As PMS is much more common than previously thought, the priority for 22q13 deletion/SHANK3 gene testing should be increased when diagnosing ASD in infants and children. There is also a high likelihood of increased demand for clinical trials targeting PMS (e.g., SHANK3 protein restoration).
• Limitations: Variation in global healthcare access and differences in diagnostic criteria may limit the accuracy of prevalence estimates.

1 sources

cdc.gov

Autism Spectrum Disorder Articles | Autism Spectrum Disorder (ASD) | CDC

2. Many Genes Have Been Linked to Autism – But a New Study Suggests It May Be Their Path to the Brain That Matters

• Author/Affiliation: Research team led by Yale University
• Journal/Source: Nature related publication, May 2026
• Study Design: Tracking developmental pathways of multiple ASD-associated genes and analyzing neurobiological convergence
• Sample: Database of hundreds of ASD-associated genes
• Key Findings: The signal transduction pathway that genes take to reach the brain is more critical for determining the ASD phenotype than the individual genes themselves. Even different genes can cause similar ASD phenotypes if they regulate the same neurodevelopmental pathways.
• Clinical/Research Implications: Precision medicine interventions should target these pathways (e.g., synapse formation, axon branching) rather than just the mutated genes. This signifies a fundamental reset for drug development and therapeutic strategies.
• Limitations: Additional functional experimental evidence is needed to verify the biological validity of pathway convergence.

3. Appeals Court Revives Lawsuits Tying Tylenol Use in Pregnancy to Autism and A.D.H.D.

• Author/Affiliation: U.S. Federal Court of Appeals
• Journal/Source: Court ruling news (2026-07-13, The New York Times)
• Study Design: Legal evidence review and scientific reliability assessment
• Sample: Lawsuits related to prenatal exposure to acetaminophen (Tylenol)
• Key Findings: While the initial court dismissed the lawsuits due to insufficient scientific evidence, the Court of Appeals decided to proceed with the trial, stating that the evidence cannot be dismissed as entirely unreliable. However, causality remains unestablished.
• Clinical/Research Implications: This case highlights the difficulty of proving causality between ASD and environmental exposures, especially medications. Clinicians should be aware that there is insufficient evidence-based support to conclude that prenatal acetaminophen use significantly increases the risk of ASD.
• Limitations: There is a gap between legal judgment and scientific consensus. The judiciary needs a reinterpretation of criteria for proving causality in epidemiological studies.

오늘의 큰 흐름

• Convergence of Genetic Pathways: The focus is shifting from the importance of individual genes to common neurodevelopmental pathways. This provides a new framework for explaining the biological heterogeneity of ASD.
• Re-evaluation of Rare Genetic Disorders: As known ASD genotypes like Phelan-McDermid syndrome show much higher prevalence than expected, readjusting the priority of early screening and genetic diagnostic strategies is necessary.
• The Challenge of Environmental Causality: Despite the demand for legal and clinical certainty, as seen in the Tylenol case, scientific consensus remains insufficient. Large-scale prospective cohorts are urgently needed.

임상가·연구자를 위한 액션 아이템

• Genetic Diagnostics: Increase the priority of SHANK3 (PMS) testing for new ASD patients and incorporate the new prevalence data (1/7,300) when interpreting test results to improve diagnostic accuracy.
• Follow-up Reading: Refer to the original full paper by the Yale team and peer commentaries on pathway analysis methodologies in Molecular Psychiatry or Biological Psychiatry.
• Caution: While the causal link between Tylenol and ASD is being re-examined in court, the evidence for causality remains insufficient to date. Avoid over-interpretation when providing prenatal medication counseling.

다음에 주목할 것

Clinical trials for SHANK3 protein restoration therapy for patients with Phelan-McDermid syndrome (currently in the IND application process) are expected to release results in the second half of this year.

Editor's Note: Unlike previous reports (2026-07-10, 2026-07-07, 2026-07-05), this issue focuses on a fundamental paradigm shift: re-evaluating the mechanisms of genetic pathways and the epidemiological definition of rare genetic disorders.